{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:46:57Z","timestamp":1793832417835,"version":"4.6.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82073370, 82272794"],"award-info":[{"award-number":["No. 82073370, 82272794"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01678-2","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T20:00:47Z","timestamp":1741118447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Anti-TGF-\u03b2\/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis"],"prefix":"10.1186","volume":"18","author":[{"given":"Yuze","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuheng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengke","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kongming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"issue":"9","key":"1678_CR1","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","volume":"20","author":"K Yang","year":"2023","unstructured":"Yang K, Halima A, Chan TA. Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy. Nat Rev Clin Oncol. 2023;20(9):604\u201323.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"1678_CR2","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, et al. Pembrolizumab for early Triple-Negative breast Cancer. N Engl J Med. 2020;382(9):810\u201321.","journal-title":"N Engl J Med"},{"issue":"21","key":"1678_CR3","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","volume":"391","author":"T Andre","year":"2024","unstructured":"Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, et al. Nivolumab plus ipilimumab in Microsatellite-Instability-High metastatic colorectal Cancer. N Engl J Med. 2024;391(21):2014\u201326.","journal-title":"N Engl J Med"},{"issue":"1","key":"1678_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"WL Guan","year":"2023","unstructured":"Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1678_CR5","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V. Estimation of the percentage of US patients with Cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535.","journal-title":"JAMA Netw Open"},{"issue":"10183","key":"1678_CR6","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr., Srimuninnimit V, Laktionov KK, Bondarenko I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330.","journal-title":"Lancet"},{"issue":"1","key":"1678_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-023-00372-8","volume":"12","author":"W Ma","year":"2023","unstructured":"Ma W, Xue R, Zhu Z, Farrukh H, Song W, Li T, Zheng L, Pan CX. Increasing cure rates of solid tumors by immune checkpoint inhibitors. Exp Hematol Oncol. 2023;12(1):10.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1678_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13045-022-01307-2","volume":"15","author":"L Xu","year":"2022","unstructured":"Xu L, Zou C, Zhang S, Chu TSM, Zhang Y, Chen W, Zhao C, Yang L, Xu Z, Dong S, et al. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. J Hematol Oncol. 2022;15(1):87.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1678_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","volume":"11","author":"Q Jia","year":"2022","unstructured":"Jia Q, Wang A, Yuan Y, Zhu B, Long H. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp Hematol Oncol. 2022;11(1):24.","journal-title":"Exp Hematol Oncol"},{"issue":"7637","key":"1678_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer\u2013immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"issue":"1","key":"1678_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","volume":"13","author":"S Zheng","year":"2024","unstructured":"Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni C. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies. Exp Hematol Oncol. 2024;13(1):80.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1678_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 challenges in Cancer immunotherapy. Immunity. 2020;52(1):17\u201335.","journal-title":"Immunity"},{"issue":"7693","key":"1678_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, et al. TGF\u03b2 attenuates tumour response to PD-L1 Blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138.","journal-title":"Nature"},{"issue":"1","key":"1678_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","volume":"22","author":"DVF Tauriello","year":"2022","unstructured":"Tauriello DVF, Sancho E, Batlle E. Overcoming TGF\u03b2-mediated immune evasion in cancer. Nat Rev Cancer. 2022;22(1):25\u201344.","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"1678_CR15","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massagu\u00e9","year":"2023","unstructured":"Massagu\u00e9 J, Sheppard D. TGF-\u03b2 signaling in health and disease. Cell. 2023;186(19):4007\u201337.","journal-title":"Cell"},{"issue":"12","key":"1678_CR16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41580-023-00638-3","volume":"24","author":"L Richardson","year":"2023","unstructured":"Richardson L, Wilcockson SG, Guglielmi L, Hill CS. Context-dependent TGF\u03b2 family signalling in cell fate regulation. Nat Rev Mol Cell Biol. 2023;24(12):876\u201394.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"1678_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Zhang J, Li A, Niu M, Yan Y, Jiao Y, Luo S, Zhou P, Wu K. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1. J Hematol Oncol. 2021;14(1):27.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1678_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/cac2.12244","volume":"42","author":"B Cheng","year":"2022","unstructured":"Cheng B, Ding K, Chen P, Ji J, Luo T, Guo X, Qiu W, Ma C, Meng X, Wang J, et al. Anti-PD-L1\/TGF-\u03b2R fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1\/PD-L1 inhibitors in lung cancer. Cancer Commun (Lond). 2022;42(1):17\u201336.","journal-title":"Cancer Commun (Lond)"},{"key":"1678_CR19","doi-asserted-by":"crossref","unstructured":"Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, Yu H, Qin G, Sircar A, Hern\u00e1ndez VM et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2. Sci Transl Med. 2018;10(424).","DOI":"10.1126\/scitranslmed.aan5488"},{"issue":"7","key":"1678_CR20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, B\u00e4hr O, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003\u201310.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1678_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"issue":"7776","key":"1678_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","volume":"574","author":"O Demaria","year":"2019","unstructured":"Demaria O, Cornen S, Da\u00ebron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45\u201356.","journal-title":"Nature"},{"issue":"1","key":"1678_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12943-023-01885-w","volume":"22","author":"M Yi","year":"2023","unstructured":"Yi M, Li T, Niu M, Mei Q, Zhao B, Chu Q, Dai Z, Wu K. Exploiting innate immunity for cancer immunotherapy. Mol Cancer. 2023;22(1):187.","journal-title":"Mol Cancer"},{"issue":"7","key":"1678_CR24","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","volume":"18","author":"N Shaverdian","year":"2017","unstructured":"Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895\u2013903.","journal-title":"Lancet Oncol"},{"issue":"24","key":"1678_CR25","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342\u201350.","journal-title":"N Engl J Med"},{"issue":"8","key":"1678_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","volume":"20","author":"L Galluzzi","year":"2023","unstructured":"Galluzzi L, Aryankalayil MJ, Coleman CN, Formenti SC. Emerging evidence for adapting radiotherapy to immunotherapy. Nat Rev Clin Oncol. 2023;20(8):543\u201357.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"1678_CR27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41571-019-0238-9","volume":"16","author":"C Grassberger","year":"2019","unstructured":"Grassberger C, Ellsworth SG, Wilks MQ, Keane FK, Loeffler JS. Assessing the interactions between radiotherapy and antitumour immunity. Nat Rev Clin Oncol. 2019;16(12):729\u201345.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1678_CR28","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ccell.2021.08.008","volume":"39","author":"Y Lan","year":"2021","unstructured":"Lan Y, Moustafa M, Knoll M, Xu C, Furkel J, Lazorchak A, Yeung TL, Hasheminasab SM, Jenkins MH, Meister S, et al. Simultaneous targeting of TGF-\u03b2\/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell. 2021;39(10):1388\u2013e14031310.","journal-title":"Cancer Cell"},{"issue":"7","key":"1678_CR29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409\u201325.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"1678_CR30","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1158\/0008-5472.CAN-14-3511","volume":"75","author":"C Vanpouille-Box","year":"2015","unstructured":"Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti SC, Barcellos-Hoff MH, Demaria S. TGF\u03b2 is a master regulator of radiation Therapy-Induced antitumor immunity. Cancer Res. 2015;75(11):2232\u201342.","journal-title":"Cancer Res"},{"issue":"9","key":"1678_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","volume":"7","author":"SK Jabbour","year":"2021","unstructured":"Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A, Houghton B, et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III Non-Small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol. 2021;7(9):1\u20139.","journal-title":"JAMA Oncol"},{"issue":"5","key":"1678_CR32","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.ijrobp.2021.12.150","volume":"112","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang T, Huang Y, Li W, Zhao J, Yang Y, Li C, Wang L, Bi N. Real-World safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage III Non-small cell lung cancer: A systematic review and Meta-analysis. Int J Radiat Oncol Biol Phys. 2022;112(5):1154\u201364.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1678_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.chest.2019.03.033","volume":"156","author":"AN Hanania","year":"2019","unstructured":"Hanania AN, Mainwaring W, Ghebre YT, Hanania NA, Ludwig M. Radiation-Induced lung injury: assessment and management. Chest. 2019;156(1):150\u201362.","journal-title":"Chest"},{"issue":"1","key":"1678_CR34","doi-asserted-by":"publisher","first-page":"e1546","DOI":"10.1002\/ctm2.1546","volume":"14","author":"M Yi","year":"2024","unstructured":"Yi M, Yuan Y, Ma L, Li L, Qin W, Wu B, Zheng B, Liao X, Hu G, Liu B. Inhibition of TGF\u03b21 activation prevents radiation-induced lung fibrosis. Clin Translational Med. 2024;14(1):e1546.","journal-title":"Clin Translational Med"},{"key":"1678_CR35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.freeradbiomed.2018.10.423","volume":"129","author":"C Bian","year":"2018","unstructured":"Bian C, Qin WJ, Zhang CY, Zou GL, Zhu YZ, Chen J, Zhao R, Wang YY, Zhe H. Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-\u03b2\/Smad3 signaling pathway in an Nrf2-dependent manner. Free Radic Biol Med. 2018;129:446\u201353.","journal-title":"Free Radic Biol Med"},{"key":"1678_CR36","doi-asserted-by":"crossref","unstructured":"Yi M, Wu Y, Niu M, Zhu S, Zhang J, Yan Y, Zhou P, Dai Z, Wu K. Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer. 2022;10(12).","DOI":"10.1136\/jitc-2022-005543"},{"issue":"7798","key":"1678_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41586-020-2054-x","volume":"579","author":"Z Lu","year":"2020","unstructured":"Lu Z, Zou J, Li S, Topper MJ, Tao Y, Zhang H, Jiao X, Xie W, Kong X, Vaz M, et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020;579(7798):284\u201390.","journal-title":"Nature"},{"key":"1678_CR38","doi-asserted-by":"crossref","unstructured":"Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, Jost C, Fransen MF, Buser RB, Kowanetz M et al. Dendritic cells dictate responses to PD-L1 Blockade cancer immunotherapy. Sci Transl Med. 2020;12(534).","DOI":"10.1126\/scitranslmed.aav7431"},{"issue":"1","key":"1678_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13045-021-01155-6","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Zhang J, Li S, Zhu S, Yan Y, Li N, Zhou P, Chu Q, Wu K. Combine and conquer: manganese synergizing anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. J Hematol Oncol. 2021;14(1):146.","journal-title":"J Hematol Oncol"},{"key":"1678_CR40","doi-asserted-by":"crossref","unstructured":"Hamon P, Gerb\u00e9 De Thor\u00e9 M, Classe M, Signolle N, Liu W, Bawa O, Meziani L, Cl\u00e9menson C, Milliat F, Deutsch E et al. TGF\u03b2 receptor Inhibition unleashes interferon-\u03b2 production by tumor-associated macrophages and enhances radiotherapy efficacy. J Immunother Cancer. 2022;10(3).","DOI":"10.1136\/jitc-2021-003519"},{"issue":"4","key":"1678_CR41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2144\/000112729","volume":"44","author":"RH H\u00fcbner","year":"2008","unstructured":"H\u00fcbner RH, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, Freitag-Wolf S, Bewig B. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques. 2008;44(4):507\u201311. 514\u2013\u2009507.","journal-title":"Biotechniques"},{"issue":"1","key":"1678_CR42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-023-01487-5","volume":"16","author":"M Niu","year":"2023","unstructured":"Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R, Zeng L, Shi J, Zhang J, Zhou P, et al. Synergistic efficacy of simultaneous anti-TGF-\u03b2\/VEGF bispecific antibody and PD-1 Blockade in cancer therapy. J Hematol Oncol. 2023;16(1):94.","journal-title":"J Hematol Oncol"},{"issue":"17","key":"1678_CR43","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1093\/bioinformatics\/btq401","volume":"26","author":"D Wu","year":"2010","unstructured":"Wu D, Lim E, Vaillant F, Asselin-Labat ML, Visvader JE, Smyth GK. ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics. 2010;26(17):2176\u201382.","journal-title":"Bioinformatics"},{"issue":"20","key":"1678_CR44","doi-asserted-by":"publisher","first-page":"8892","DOI":"10.18632\/aging.102329","volume":"11","author":"T Yang","year":"2019","unstructured":"Yang T, Huang T, Zhang D, Wang M, Wu B, Shang Y, Sattar S, Ding L, Liu Y, Jiang H, et al. TGF-\u03b2 receptor inhibitor LY2109761 enhances the radiosensitivity of gastric cancer by inactivating the TGF-\u03b2\/SMAD4 signaling pathway. Aging. 2019;11(20):8892\u2013910.","journal-title":"Aging"},{"issue":"1","key":"1678_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","volume":"27","author":"K Ganesh","year":"2021","unstructured":"Ganesh K, Massagu\u00e9 J. Targeting metastatic cancer. Nat Med. 2021;27(1):34\u201344.","journal-title":"Nat Med"},{"issue":"20","key":"1678_CR46","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1158\/0008-5472.CAN-22-3707","volume":"83","author":"N Cohen","year":"2023","unstructured":"Cohen N, Mundhe D, Deasy SK, Adler O, Ershaid N, Shami T, Levi-Galibov O, Wassermann R, Scherz-Shouval R, Erez N. Breast Cancer-Secreted factors promote lung metastasis by signaling systemically to induce a fibrotic premetastatic niche. Cancer Res. 2023;83(20):3354\u201367.","journal-title":"Cancer Res"},{"issue":"3","key":"1678_CR47","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1158\/0008-5472.CAN-20-1865","volume":"81","author":"CH Chuang","year":"2021","unstructured":"Chuang CH, Dorsch M, Dujardin P, Silas S, Ueffing K, H\u00f6lken JM, Yang D, Winslow MM, Gr\u00fcner BM. Altered mitochondria functionality defines a metastatic cell state in lung Cancer and creates an exploitable vulnerability. Cancer Res. 2021;81(3):567\u201379.","journal-title":"Cancer Res"},{"issue":"9","key":"1678_CR48","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1002\/bjs.11789","volume":"107","author":"M Baum","year":"2020","unstructured":"Baum M, Fallowfield L, Farewell V, Macbeth F, Treasure T. NICE guidelines: management of colorectal cancer metastases. Br J Surg. 2020;107(9):e357.","journal-title":"Br J Surg"},{"key":"1678_CR49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.biomaterials.2017.05.022","volume":"137","author":"DS Liang","year":"2017","unstructured":"Liang DS, Zhang WJ, Wang AT, Su HT, Zhong HJ, Qi XR. Treating metastatic triple negative breast cancer with CD44\/neuropilin dual molecular targets of multifunctional nanoparticles. Biomaterials. 2017;137:23\u201336.","journal-title":"Biomaterials"},{"key":"1678_CR50","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.2147\/IJN.S419712","volume":"18","author":"C He","year":"2023","unstructured":"He C, Ding H, Li L, Chen J, Mo X, Ding Y, Chen W, Tang Q, Wang Y. Gold nanoparticles enhance the ability of radiotherapy to induce Immunogenic cell death in glioblastoma. Int J Nanomed. 2023;18:5701\u201312.","journal-title":"Int J Nanomed"},{"issue":"3","key":"1678_CR51","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.immuni.2017.08.016","volume":"47","author":"C Goudot","year":"2017","unstructured":"Goudot C, Coillard A, Villani AC, Gueguen P, Cros A, Sarkizova S, Tang-Huau TL, Bohec M, Baulande S, Hacohen N, et al. Aryl hydrocarbon receptor controls monocyte differentiation into dendritic cells versus macrophages. Immunity. 2017;47(3):582\u2013e596586.","journal-title":"Immunity"},{"issue":"5","key":"1678_CR52","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, et al. STING-Dependent cytosolic DNA sensing promotes Radiation-Induced type I Interferon-Dependent antitumor immunity in Immunogenic tumors. Immunity. 2014;41(5):843\u201352.","journal-title":"Immunity"},{"issue":"7","key":"1678_CR53","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","volume":"11","author":"L Corrales","year":"2015","unstructured":"Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11(7):1018\u201330.","journal-title":"Cell Rep"},{"issue":"4","key":"1678_CR54","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","volume":"20","author":"M McLaughlin","year":"2020","unstructured":"McLaughlin M, Patin EC, Pedersen M, Wilkins A, Dillon MT, Melcher AA, Harrington KJ. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020;20(4):203\u201317.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1678_CR55","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1038\/s41467-023-40844-3","volume":"14","author":"NP Rudqvist","year":"2023","unstructured":"Rudqvist NP, Charpentier M, Lhuillier C, Wennerberg E, Spada S, Sheridan C, Zhou XK, Zhang T, Formenti SC, Sims JS, et al. Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors. Nat Commun. 2023;14(1):5146.","journal-title":"Nat Commun"},{"issue":"4","key":"1678_CR56","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.ijrobp.2019.03.022","volume":"104","author":"A Li","year":"2019","unstructured":"Li A, Barsoumian HB, Schoenhals JE, Caetano MS, Wang X, Menon H, Valdecanas DR, Niknam S, Younes AI, Cortez MA, et al. IDO1 Inhibition overcomes Radiation-Induced rebound immune suppression by reducing numbers of IDO1-Expressing Myeloid-Derived suppressor cells in the tumor microenvironment. Int J Radiat Oncol Biol Phys. 2019;104(4):903\u201312.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"1678_CR57","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1053\/j.gastro.2016.02.070","volume":"150","author":"L Seifert","year":"2016","unstructured":"Seifert L, Werba G, Tiwari S, Giao Ly NN, Nguy S, Alothman S, Alqunaibit D, Avanzi A, Daley D, Barilla R, et al. Radiation therapy induces macrophages to suppress T-Cell responses against pancreatic tumors in mice. Gastroenterology. 2016;150(7):1659\u2013e16721655.","journal-title":"Gastroenterology"},{"key":"1678_CR58","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40425-016-0204-3","volume":"5","author":"GG Hillman","year":"2017","unstructured":"Hillman GG, Reich LA, Rothstein SE, Abernathy LM, Fountain MD, Hankerd K, Yunker CK, Rakowski JT, Quemeneur E, Slos P. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. J Immunother Cancer. 2017;5:4.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1678_CR59","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18(12):792\u2013804.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1678_CR60","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/1078-0432.CCR-21-3570","volume":"28","author":"A Obradovic","year":"2022","unstructured":"Obradovic A, Graves D, Korrer M, Wang Y, Roy S, Naveed A, Xu Y, Luginbuhl A, Curry J, Gibson M, et al. Immunostimulatory cancer-Associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer. Clin Cancer Res. 2022;28(10):2094\u2013109.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1678_CR61","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2022.01.004","volume":"40","author":"AM Nicolas","year":"2022","unstructured":"Nicolas AM, Pesic M, Engel E, Ziegler PK, Diefenhardt M, Kennel KB, Buettner F, Conche C, Petrocelli V, Elwakeel E, et al. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell. 2022;40(2):168\u2013e184113.","journal-title":"Cancer Cell"},{"issue":"1","key":"1678_CR62","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1678_CR63","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41(3):450\u201365.","journal-title":"Cancer Cell"},{"issue":"1","key":"1678_CR64","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-024-00539-x","volume":"13","author":"Y Yin","year":"2024","unstructured":"Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S, Xu X, Nie Y, Fan D, Wu K, et al. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. Exp Hematol Oncol. 2024;13(1):72.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1678_CR65","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","volume":"17","author":"KY Shen","year":"2024","unstructured":"Shen KY, Zhu Y, Xie SZ, Qin LX. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J Hematol Oncol. 2024;17(1):25.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"1678_CR66","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nm.4086","volume":"22","author":"T Saito","year":"2016","unstructured":"Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016;22(6):679\u201384.","journal-title":"Nat Med"},{"issue":"7547","key":"1678_CR67","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint Blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373\u20137.","journal-title":"Nature"},{"issue":"4","key":"1678_CR68","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.ijrobp.2014.03.048","volume":"89","author":"J Mahmood","year":"2014","unstructured":"Mahmood J, Jelveh S, Zaidi A, Doctrow SR, Medhora M, Hill RP. Targeting the Renin-angiotensin system combined with an antioxidant is highly effective in mitigating radiation-induced lung damage. Int J Radiat Oncol Biol Phys. 2014;89(4):722\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1678_CR69","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1165\/rcmb.2017-0096ST","volume":"56","author":"RG Jenkins","year":"2017","unstructured":"Jenkins RG, Moore BB, Chambers RC, Eickelberg O, K\u00f6nigshoff M, Kolb M, Laurent GJ, Nanthakumar CB, Olman MA, Pardo A, et al. An official American thoracic society workshop report: use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis. Am J Respir Cell Mol Biol. 2017;56(5):667\u201379.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"1678_CR70","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.molcel.2019.04.005","volume":"74","author":"X Tu","year":"2019","unstructured":"Tu X, Qin B, Zhang Y, Zhang C, Kahila M, Nowsheen S, Yin P, Yuan J, Pei H, Li H, et al. PD-L1 (B7-H1) competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy. Mol Cell. 2019;74(6):1215\u2013e12261214.","journal-title":"Mol Cell"},{"issue":"6","key":"1678_CR71","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, et al. Tumor interferon signaling regulates a Multigenic resistance program to immune checkpoint Blockade. Cell. 2016;167(6):1540\u2013e15541512.","journal-title":"Cell"},{"issue":"8","key":"1678_CR72","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","volume":"27","author":"JM Kim","year":"2016","unstructured":"Kim JM, Chen DS. Immune escape to PD-L1\/PD-1 Blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492\u2013504.","journal-title":"Ann Oncol"},{"issue":"4","key":"1678_CR73","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","volume":"21","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo I, Ad\u00e1n-Barrientos I, Gal\u00e1n M, Wculek SK, Sancho D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Rev Clin Oncol. 2024;21(4):257\u201377.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1678_CR74","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","volume":"15","author":"M Wu","year":"2022","unstructured":"Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, Xia Y. Improvement of the anticancer efficacy of PD-1\/PD-L1 Blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1678_CR75","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","volume":"1","author":"SA Oh","year":"2020","unstructured":"Oh SA, Wu DC, Cheung J, Navarro A, Xiong H, Cubas R, Totpal K, Chiu H, Wu Y, Comps-Agrar L, et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer. 2020;1(7):681\u201391.","journal-title":"Nat Cancer"},{"issue":"18","key":"1678_CR76","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1158\/0008-5472.CAN-23-0613","volume":"83","author":"S Fattori","year":"2023","unstructured":"Fattori S, Le Roy A, Houacine J, Robert L, Abes R, Gorvel L, Granjeaud S, Rouvi\u00e8re MS, Ben Amara A, Boucherit N, et al. CD25high effector regulatory T cells hamper responses to PD-1 Blockade in Triple-Negative breast Cancer. Cancer Res. 2023;83(18):3026\u201344.","journal-title":"Cancer Res"},{"issue":"10","key":"1678_CR77","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.medj.2024.06.002","volume":"5","author":"H Wang","year":"2024","unstructured":"Wang H, Yao Z, Kang K, Zhou L, Xiu W, Sun J, Xie C, Yu M, Li Y, Zhang Y, et al. Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. Med. 2024;5(10):1237\u2013e12541239.","journal-title":"Med"},{"issue":"5","key":"1678_CR78","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et al. Low-dose irradiation programs macrophage differentiation to an iNOS\u207a\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24(5):589\u2013602.","journal-title":"Cancer Cell"},{"issue":"1","key":"1678_CR79","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, et al. Low-Dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 2022;12(1):108\u201333.","journal-title":"Cancer Discov"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01678-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01678-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01678-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T07:43:16Z","timestamp":1741160596000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01678-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1678"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01678-2","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal operations in this study were evaluated and approved by the Animal Ethics Committee of Hubei Safety Evaluation Center (permit number: 202310005). All procedures adhered to protocols approved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JZ and PZ were employees of Wuhan YZY Biopharma Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}